drugset / Trial / NCT05504642
Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to use Chemo-radio-immunotherapy and maintenance therapy with Nivolumab and Ipilimumab in order to achieve improved outcome in patients with locally advanced cervical cancer.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2026-06
- Completion
- 2026-07
Outcome
Outcome not reported
Stopped (Business): “Study stopped before submission for funding reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | — |